Cardiovascular Division University of Minnesota Minneapolis MN.
Williamson County Medical Center Nashville TN.
J Am Heart Assoc. 2020 Mar 3;9(5):e015221. doi: 10.1161/JAHA.119.015221. Epub 2020 Feb 21.
Background Pulmonary arterial hypertension (PAH) is a lethal disease. In resource-limited countries PAH outcomes are worse because therapy costs are prohibitive. To improve global outcomes, noninvasive and widely available biomarkers that identify high-risk patients should be defined. Serum chloride is widely available and predicts mortality in left heart failure, but its prognostic utility in PAH requires further investigation. Methods and Results In this study 475 consecutive PAH patients evaluated at the University of Minnesota and Vanderbilt University PAH clinics were examined. Clinical characteristics were compared by tertiles of serum chloride. Both the Kaplan-Meier method and Cox regression analysis were used to assess survival and predictors of mortality, respectively. Categorical net reclassification improvement and relative integrated discrimination improvement compared prediction models. PAH patients in the lowest serum chloride tertile (≤101 mmol/L: hypochloremia) had the lowest 6-minute walk distance and highest right atrial pressure despite exhibiting no differences in pulmonary vascular disease severity. The 1-, 3-, and 5-year survival was reduced in hypochloremic patients when compared with the middle- and highest-tertile patients (86%/64%/44%, 95%/78%/59%, and, 91%/79%/66%). After adjustment for age, sex, diuretic use, serum sodium, bicarbonate, and creatinine, the hypochloremic patients had increased mortality when compared with the middle-tertile and highest-tertile patients. The Minnesota noninvasive model (functional class, 6-minute walk distance, and hypochloremia) was as effective as the French noninvasive model (functional class, 6-minute walk distance, and elevated brain natriuretic peptide or N-terminal pro-brain natriuretic peptide) for predicting mortality. Conclusions Hypochloremia (≤101 mmol/L) identifies high-risk PAH patients independent of serum sodium, renal function, and diuretic use.
肺动脉高压(PAH)是一种致命疾病。在资源有限的国家,由于治疗费用过高,PAH 患者的预后更差。为了改善全球预后,需要定义能够识别高危患者的非侵入性和广泛可用的生物标志物。血清氯广泛可用,可预测左心衰竭患者的死亡率,但在 PAH 中的预后作用仍需进一步研究。
本研究共纳入在明尼苏达大学和范德比尔特大学 PAH 诊所接受评估的 475 例连续 PAH 患者。通过血清氯的三分位值比较临床特征。分别采用 Kaplan-Meier 法和 Cox 回归分析评估生存和死亡率预测因素。采用分类净重新分类改善和相对综合判别改善比较预测模型。血清氯最低三分位组(≤101mmol/L:低氯血症)的 6 分钟步行距离最短,右心房压力最高,尽管其肺血管疾病严重程度无差异。与中、高三分位组相比,低氯血症患者的 1、3 和 5 年生存率降低(86%/64%/44%、95%/78%/59%和 91%/79%/66%)。校正年龄、性别、利尿剂使用、血清钠、碳酸氢盐和肌酐后,与中三分位组和高三分位组相比,低氯血症患者的死亡率更高。明尼苏达非侵入性模型(功能分级、6 分钟步行距离和低氯血症)与法国非侵入性模型(功能分级、6 分钟步行距离和脑利钠肽或 N 端脑利钠肽升高)预测死亡率的效果相当。
低氯血症(≤101mmol/L)可识别出独立于血清钠、肾功能和利尿剂使用的高危 PAH 患者。